Wednesday, December 20, 2023 CO26 secondary publication Chen EX, Loree JM, Titmuss E, Jonker DJ, Kennecke HF, Berry S, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M, Colwell B, Samimi S, Samson B, Abbas T, Aucoin N, Aubin F, Koski S, Wei AC, Tu D, O’Callaghan CJ. Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Network Open 6: e2346094-e2346094. 2023. https://doi.org/10.1001/jamanetworkopen.2023.46094 In this secondary analysis of a randomized clinical trial of 180 patients, those without LM had significantly improved progression-free and overall survival. In patients without LM, durvalumab and tremelimumab treatment was associated with improved progression-free survival and disease control rate, not overall survival. Future clinical trials of immune checkpoint inhibitors in microsatellite-stable or mismatch repair–proficient advanced colorectal cancer should stratify patients according to the presence of LM and focus on understanding the mechanism of resistance by LM.
